New trial
LASER - Phase 2 Trial of 177Lu-PSMA-617 in PSMA-Positive ccRCC
- Trial ID
- NCT06964958 on ClinicalTrials.gov
- Cancer type
- Clear Cell Renal Cell Carcinoma
- Published in
- New in Oncology - June 6, 2025
Dana-Farber is evaluating 177Lu-PSMA-617—a radioligand therapy delivering beta radiation via lutetium-177 vipivotide tetraxetan—as a systemic treatment in PSMA-positive advanced/metastatic clear cell renal cell carcinoma in a 2nd line+ setting.
More in kidney cancer
-
Trial result · Oct 22, 2026 · NCT05805501
Tobemstomig (PD-1×LAG-3) ± tiragolumab (anti-TIGIT) + axitinib adds toxicity without PFS/ORR gain in 1L ccRCC -
New trial · Oct 15, 2026 · NCT07848295
Phase 1 BMS-986527 allogeneic CD70 CAR T-cell therapy is tested alone or with nivolumab or cabozantinib in clear cell RCC -
Trial result · Sep 24, 2026 · NCT04195750
Improving HRQoL Correlates With Longer PFS/OS in LITESPARK-005 -
Trial result · Sep 24, 2026 · NCT04987203
Tivozanib (VEGFR TKI) Beats Tivozanib+nivolumab in post-ICI mRCC, extending 2L PFS -
Trial result · Sep 24, 2026 · NCT05536141
Casdatifan (HIF-2α inhibitor) Monotherapy in Late-Line ccRCC Shows Class-On-Target Anemia/Hypoxia With Low Discontinuation